Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma

  title={Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma},
  author={M. Yamamoto and Shigeki Arii and Katsuhiko Sugahara and Takayoshi Tobe},
  journal={British Journal of Surgery},
Adjuvant oral chemotherapy was studied in 67 patients with stage II hepatocellular carcinoma who underwent curative resection between May 1988 and December 1990. Patients were stratified into two groups according to preoperative liver dysfunction: 55 had stage I disease (mild dysfunction) and 12 had stage II (moderate dysfunction). A randomized controlled study of postoperative oral administration of 1‐hexylcarbamoyl‐5‐fluorouracil (HCFU) was conducted in each group. From October 1994 HCFU… 

Prospective Case-controlled Trial of Adjuvant Chemotherapy after Resection of Hepatocellular Carcinoma

Postoperative adjuvant chemotherapy using the present regimen has a tendency to reduce tumor recurrence rate and may improve long-term survival for high risk patients.

Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial

Postoperative adjuvant therapy with capecitabine is well tolerated, postpones the recurrence of HCC, and reduces the risk of tumor recurrence, and is likely to improve postoperative survival.

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.

In a group of patients who underwent curative resection of hepatocellular carcinoma, postoperative adjuvant chemotherapy using the present regimen was associated with more frequent extrahepatic recurrences and a worse outcome.

Adjuvant treatment strategy after curative resection for hepatocellular carcinoma

The available evidence for the efficiency of adjuvant treatments to prevent HCC recurrence after curative liver resection is evaluated, and Huaier granule, a traditional Chinese medicine, has been proved to be effective in prolonging the recurrence-free survival and reducing extrahepatic recurrence.

Uracil‐tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial

The results offer no evidence to support potential benefits of adjuvant chemotherapy with UFT after surgery in patients with HCC and suggest that such treatment may even worsen overall survival.

Adjuvant Chemolipiodolization Reduces Early Recurrence Derived from Intrahepatic Metastasis of Hepatocellular Carcinoma After Hepatectomy

Adjuvant chemolipiodolization can reduce the risk of early recurrences, which would be mainly IM derived, but it did not reduce late phase Recurrence-free survival and was not an independent favorable prognostic factor for 5-year overall survival.

Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials.

Several adjuvant approaches have been studied for their efficacy on recurrence in HCC patients in randomized control trials; however, multi-centric randomized control trial is still needed for further evaluation on their efficacy and systemic or local toxicities.

Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population‑based cohort study

Although there was no significant difference in survival analysis between the chemotherapy and non-chemotherapy groups, the cumulative cancer-specific mortality of most HCC patients were decreased in chemotherapy group, and population-based estimates of the prognostic factors in HCC Patients with or without chemotherapy were provided.

Adjuvant Therapy for Hepatocellular Carcinoma: Is There an Effective Modality?

The evidence that new interventions including retinoid, immunotherapy, and interferon had significant impact on prevention of recurrence of HCC after curative surgery has accumulated has accumulated, but the recommendation of its routine clinical use remains to be confirmed.



Clinical management of recurrent hepatocellular carcinoma after primary resection

Serial measurement of serum α‐fetoprotein (AFP) was useful for the detection of recurrences, however, the levels of AFP seem to be a non‐specific, unreliable test for such patients since this tumour marker showed different ranges before the primary surgery and at the time of recurrence in 5 of the 41 patients.

Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis

It is indicated that liver transplantation might be envisaged for the treatment of cirrhotic patients with resectable hepatocellular carcinoma with high recurrence rate after resection, even with careful evaluation of tumor extension.

Prediction of Recurrence after HCC Resection

The present study suggested that, even in patients with small HCC, minute concomitant tumors invisible by conventional imaging techniques may exist at the time of surgery.

Overview of the general rules for the clinical and pathological study of primary liver cancer in Japan

The General Rules for the Clinical and Pathological Study of Primary Liver Cancer provides guidelines for case management and research in Japan and clinical classifications have been established to aide research and treatment.

Metabolic fate on 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil in mice bearing ascites sarcoma 180.

Patterns of metabolism and disposition in plasma of tumor-bearing mice after oral administration of [6(-14)C]1-hexylcarbamoyl-5-fluorouracil ([6(-14)C]HCFU) resembled those in plasma of normal mice,